M&G Investments

To add a bio or update investment portfolio, please click update information.

Investment Portfolio

bit.bio announces £40m Series C from M&G Investments to pioneer human cell programming technology

10 Jan 2026

bit.bio announces £40m Series C from M&G Investments to pioneer human cell programming technology

bit.bio develops human cell programming technology that produces consistent, scalable human cells for research, drug discovery and toxicology, helping pharmaceutical and biotech companies reduce reliance on animal testing and improve predictive accuracy.

M&G Investments

- Life Sciences
1(12 months)
mandg.com/investments/gb
Update Information

More venture news

9fin
31 Mar 2026
9fin secures £130m Series C led by HarbourVest to build clearer view of debt markets
Series CFintech
Tropic
12 Mar 2026
Tropic secures £80m Series C led by Forbion and Corteva for gene-edited tropical crop varieties
Series CAgriculture
Nscale
9 Mar 2026
Nscale raises £1.5bn Series C led by Aker ASA and 8090 Industries to deploy AI infrastructure globally
Series CAI

M&G Investments

Investment Portfolio

bit.bio announces £40m Series C from M&G Investments to pioneer human cell programming technology

More venture news

9fin secures £130m Series C led by HarbourVest to build clearer view of debt markets

Tropic secures £80m Series C led by Forbion and Corteva for gene-edited tropical crop varieties

Nscale raises £1.5bn Series C led by Aker ASA and 8090 Industries to deploy AI infrastructure globally